Oscar Bortolami

Phase 3 study (inMIND) of tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Clinical characteristics and outcomes of patients receiving second-line treatment

Ajay K. Gopal, Marek Trněný, Laurie H. Sehn, Julie M. Wu et autres

Abstract Introduction: In patients (pts) with follicular lymphoma (FL) durability of response in second-line (2L) therapy is important, as prognosis worsens and burden increases with subsequent lines of therapy. Chemoimmunotherapy is often used as 1L; however, immunotherapy is preferred for relapsed or …

us, cz, ca, be, it (code pays fourni par la source)

Phase 3 study (inMIND) of tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Clinical characteristics and outcomes by age

Christina Poh, Francisco J. Hernandez‐Ilizaliturri, Marek Trněný, Julie M. Wu et autres

Abstract Introduction Incidence of follicular lymphoma (FL) increases with age and patients (pts) often relapse, requiring multiple lines of therapy. Tafasitamab (tafa), a humanized CD19-targeting monoclonal antibody (mAb), in combination with lenalidomide (len) + rituximab (R) was recently approved for treatment of …

us, cz, be, ca (code pays fourni par la source)

Phase 3 study (inMIND) of tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Clinical characteristics and outcomes of high-risk patients

K. Huebel, Paolo Strati, Laurie H. Sehn, Julie M. Wu et autres

Abstract Introduction: Despite initial response to first-line therapy, most patients (pts) with follicular lymphoma (FL) experience relapse requiring multiple lines of therapy. A need exists for treatments that are effective in all pts including those with high-risk disease. Tafasitamab (tafa) is a …

de, us, ca, be (code pays fourni par la source)

IBCL-625: Quality of Life (QoL) Outcomes With Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma (R/R FL): Results From a Phase 3, Double-Blind, Randomized, Placebo-Controlled, International, Multicenter Study (inMIND)

Paolo Strati, Christina Poh, Marek Trněný, Kai Hübel et autres

POSTER: IBCL-625 Quality of Life (QoL) Outcomes With Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma (R/R FL): Results From a Phase 3, Double-Blind, Randomized, Placebo-Controlled, International, Multicenter Study (inMIND)

Paolo Strati, Christina Poh, Marek Trněný, Kai Hübel et autres

us, cz, de, it, es, gb, se, ca (code pays fourni par la source)

Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis

Scott D. Newsome, Ewa Krzystanek, Krzysztof Selmaj, Michal Dufek et autres

234 | POST HOC ANALYSIS OF OUTCOMES BY POD24 STATUS FROM THE inMIND STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

Laurie H. Sehn, Kai Hübel, Stefano Luminari, Christian W. Scholz et autres

ca, de, it, gb, se, au, es, kr, jp, us, fr, be, cz (code pays fourni par la source)

28 | OUTCOMES FROM THE PHASE 3 inMIND STUDY OF TAFASITAMAB (TAFA) PLUS LENALIDOMIDE (LEN) AND RITUXIMAB (R) FOR PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)

Laurie H. Sehn, Kai Hübel, Stefano Luminari, Christian W. Scholz et autres

ca, de, it, es, gb, se, gr, au, kr, jp, us, fr, be, cz (code pays fourni par la source)

Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis

Scott D. Newsome, Ewa Krzystanek, Krzysztof Selmaj, Michal Dufek et autres

BACKGROUND AND OBJECTIVES: IV-administered ocrelizumab (OCR) is approved for the treatment of relapsing and primary progressive multiple sclerosis (RMS/PPMS). OCARINA II (NCT05232825) was designed to demonstrate noninferiority in drug exposure of OCR subcutaneous (SC) vs IV administration. METHODS: ); other end points …

us, pl, cz, it, ch, gb, ca (code pays fourni par la source)

179. Ocrelizumab Subcutaneous Injection in Patients with Multiple Sclerosis: Further Characterisation of the Benefit–risk Profile from the OCARINA Clinical Development Programme

Scott D. Newsome, Ewa Krzystanek, Krzysztof Selmaj, Lawrence Goldstick et autres

us, pl, ch, gb, it (code pays fourni par la source)

Subcutaneous ocrelizumab in multiple sclerosis: results of the phase Ib dose-finding OCARINA I study

Newsome Scott, Goldstick Lawrence, Townsend Ben, Oscar Bortolami et autres

Objectives OCARINA I (NCT03972306) is a Phase Ib, dose-finding study exploring a novel subcutaneous formulation for ocrelizumab relapsing and primary progressive multiple sclerosis (RMS/PPMS), every six months. Methods Adult patients with RMS/PPMS were enrolled in two groups: prior ocrelizumab treatment (A) or …

us, ch, gb (code pays fourni par la source)

Subcutaneous ocrelizumab in patients with multiple sclerosis: results of the phase III OCARINA II study

Krzystanek Ewa, Selmaj Krzysztof, Figueiredo Catarina, Oscar Bortolami et autres

Objectives OCARINA II (NCT05232825) is a Phase III, randomised, open-label, controlled study of a novel subcutaneous formulation of ocrelizumab, designed to demonstrate non-inferior serum exposure of subcutaneous vs intravenous administration in relapsing and primary progressive multiple sclerosis (RMS/PPMS). Methods Patients were randomised …

us, pl, ch, gb, it (code pays fourni par la source)